93 completed, 17 recruiting, 14 terminated, 13 unknown. 59 Phase 2, 42 Phase 1, 29 Not applicable, 20 Phase 3, 2 Early Phase 1.
Follow Peanut Hypersensitivity: new trials by email Literature Review of Peanut Hypersensitivity trials Research Report on Peanut Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Flow CAST® Peanut Trial Basophil activation test - Peanut Allergies | Not yet recruiting | Bühlmann Laboratories AG | 245 | 2026-10-01 | 2026-08-20 | |
| A Randomized Controlled Trial of Oral Immunotherapy Versus Allergen Avoidance in Children Under 2 Years With Food Allergy Oral immunotheraphy (OIT) - Food Allergy in Children, Oral Immunotherapy for Food Allergy | Not applicable | Not yet recruiting | Copenhagen Studies on Asthma in Childhood | 120 | 2026-09-01 | 2026-09-17 |
| Efficacy, Safety and Pharmacokinetics of LP-003 in Peanut Allergic Patients LP-003 Injection, Placebo Injection - Peanut Allergies | Phase 2 | Not yet recruiting | Longbio Pharma (Suzhou) Co., Ltd. | 80 | 2026-09-01 | 2026-08-25 |
| Multi-Food Oral Immunotherapy for Peanut and Tree Nuts Multi-Food Oral Immunotherapy (Multi-OIT) with Peanut and Tree Nuts Proteins, Standard of Care (Elimination Diet) - Food Allergies, Food Allergy in Children | Not applicable | Not yet recruiting | Medical University of Warsaw | 39 | 2026-09-01 | 2026-08-13 |
| A 52-week Study of Remibrutinib in IgE-mediated Food Allergy Remibrutinib, Placebo - IgE-Mediated Food Allergy, Peanut Allergy | Phase 3 | Recruiting | Novartis Pharmaceuticals | 576 | 2026-08-27 | 2026-10-13 |
| Study of Oral Food Challenge Biomarkers (SAFER) Oral Food Challenge (OFC): Peanut Protein - Allergy | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 500 | 2026-08-20 | 2026-10-23 | |
| Comparing Standard and Autoclaved Peanut Oral Immunotherapy in People With Peanut Allergy Autoclaved peanut oral immunotherapy, Blanched peanut oral immunotherapy - Peanut Allergy | Phase 2 | Not yet recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 57 | 2026-08-01 | 2026-03-03 |
| Efficacy of Tezepelumab in Peanut Oral Immunotherapy Tezepelumab, Peanut Oral Immunotherapy (OIT), Placebo for Tezepelumab - Peanut Allergy | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 62 | 2026-07-27 | 2026-10-22 |
| Safety of MOON101 for the Treatment of Peanut Allergy Dose A, Dose B, Dose C - Peanut Allergy | Phase 1 | Suspended | Moonlight Therapeutics, Inc. | 40 | 2026-06-29 | 2026-10-16 |
| Single Ascending and Multiple Ascending Dose Study of LCA-0061 LCA-0061, Placebo - Atopic Disease, Peanut Allergies | Phase 1 | Recruiting | Lycia Therapeutics, Inc. | 72 | 2026-06-26 | 2026-07-14 |
| BÜHLMANN BAT (Basophil Activation Test) in Allergy Diagnosis (Exploratory Pilot Study) Allergy Testing, Peanut Allergies | Completed | Bühlmann Laboratories AG | 38 | 2026-05-15 | 2026-07-17 | |
| A Phase 1 Study of Cizutamig in IgE Mediated Diseases Cizutamig - IgE-Mediated Hypersensitivity, IgE Mediated Food Allergy | Phase 1 | Withdrawn | Candid Therapeutics | 2026-04-01 | 2026-07-22 | |
| UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies UKK-0018 - Peanut-Induced Anaphylaxis, Peanut Allergy | Phase 1 / Phase 2 | Recruiting | Ukko Inc | 40 | 2026-02-18 | 2026-10-16 |
| A Long Term, Observational Follow-Up Study of Children and Young People Who Underwent an 18-Month Course of Oral Immunotherapy Treatment for Peanut, Egg or Milk Allergy (5-15 Years Post-Treatment) Food Allergies, Peanut Allergies | Recruiting | Murdoch Childrens Research Institute | 147 | 2026-01-13 | 2026-02-02 | |
| Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants ENP-501, Placebo - Peanut Allergy | Phase 1 / Phase 2 | Recruiting | N-Fold, LLC | 68 | 2025-12-16 | 2026-04-24 |
| Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy MY006 Low Dose, MY006 Mid Dose, MY006 High Dose - Peanut Allergies | Phase 1 | Recruiting | Mabylon AG | 48 | 2025-12-06 | 2026-10-20 |
| Pathway to Peanut Tolerance Peanut Oral Immunotherapy (OIT) - Food Allergy in Children, Food Allergy Peanut | Not applicable | Recruiting | Chinese University of Hong Kong | 125 | 2025-11-15 | 2026-05-19 |
| PK/PD Study of IN-001 Sublingual Spray in Healthy Adults Epinephrine Auto-Injector 0.3 mg/0.3 mL, Epinephrine 0.3 mg intramuscular manual injection via a syringe and needle, IN-001 9.06 mg Sublingual Spray - Food Allergy, Anaphylaxis | Phase 1 | Completed | Insignis Therapeutics, Inc. | 32 | 2025-10-24 | 2026-05-05 |
| Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy RPT904, Placebo - Ig-E Mediated Food Allergy | Phase 2 | Recruiting | RAPT Therapeutics, Inc., a member of the GSK plc group of companies | 100 | 2025-10-22 | 2026-07-28 |
| Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg Consumption, Avoidance - Allergy and Immunology, Peanut and Nut Allergy | Not applicable | Recruiting | University of Rochester | 500 | 2025-08-01 | 2026-10-08 |
Showing 20 of 164. Sign in to see all of them.
Food Hypersensitivity (75) · Hypersensitivity (37) · Nut Hypersensitivity (16) · Anaphylaxis (12) · Egg Hypersensitivity (12) · Hypersensitivity, Immediate (11) · Milk Hypersensitivity (10) · Dermatitis, Atopic (4) · Immune System Diseases (4) · Nut and Peanut Hypersensitivity (4) · Rhinitis, Allergic (3) · Wheat Hypersensitivity (3) · Asthma (2) · Eczema (2)
Immune System Diseases (160) · Nut and Peanut Hypersensitivity (160) · Hypersensitivity, Immediate (153) · Hypersensitivity (127) · Food Hypersensitivity (89) · Dermatitis (5) · Skin Diseases (5) · Skin Diseases, Eczematous (5) · Skin and Connective Tissue Diseases (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Nose Diseases (4) · Otorhinolaryngologic Diseases (4) · Respiratory Hypersensitivity (4) · Respiratory Tract Diseases (4)
Omalizumab (8) · Capsules (4) · Immunotherapy (4) · dupilumab (3) · ligelizumab (3) · Basophil Degranulation Test (2) · Blood Specimen Collection (2) · Standard of Care (2) · remibrutinib (2) · Abatacept (1) · Anti-Bacterial Agents (1) · Diet (1) · Economics (1) · Educational Status (1) · Elimination Diets (1)
DBV Technologies (13) · University of North Carolina, Chapel Hill (13) · National Institute of Allergy and Infectious Diseases (NIAID) (12) · Aimmune Therapeutics, Inc. (10) · Johns Hopkins University (7) · Massachusetts General Hospital (5) · Novartis Pharmaceuticals (5) · Medical University of Warsaw (4) · University Hospital, Montpellier (4) · Imperial College London (3) · McGill University Health Centre/Research Institute of the McGill University Health Centre (3) · Stanford University (3) · Alladapt Immunotherapeutics, Inc. (2) · Astellas Pharma Global Development, Inc. (2) · Bühlmann Laboratories AG (2)
United States (97) · Canada (29) · France (18) · United Kingdom (17) · Australia (14) · Germany (13) · Netherlands (11) · Spain (10) · Ireland (9) · Italy (6) · Sweden (6) · Poland (5) · Denmark (4) · Hong Kong (2) · Japan (2)
Wesley Burks, MD (11) · Scott Sicherer, MD (6) · Robert Wood, MD (5) · Wayne G Shreffler, MD, PhD (5) · Edwin Kim, MD (4) · Arvil W Burks, MD (2) · Gideon Lack, MD (2) · Hugh A. Sampson, MD (2) · Hugh Sampson, MD (2) · Jerry Staser (2) · Mei-Lun Wang, MD (2)
PMID 34389504, PMID 38814736, PMID 34320250, PMID 36915184, PMID 30978404, PMID 32414772, PMID 33463542, PMID 33715235, PMID 37163622, PMID 38010254, PMID 41615410, PMID 19226304, PMID 19477496, PMID 19577283, PMID 20451041, PMID 21035177, PMID 21281959, PMID 21414048, PMID 22236732, PMID 22732173, PMID 23174658, PMID 23265698, PMID 23273958, PMID 24314292, PMID 24636473, PMID 25457149, PMID 25528358, PMID 25656999, PMID 25705822, PMID 25705823, PMID 25925398, PMID 26920463, PMID 27297994, PMID 27522159, PMID 27883239, PMID 28091362, PMID 29136445, PMID 29408715, PMID 29700872, PMID 29709643, PMID 30225844, PMID 30449234, PMID 30794314, PMID 31013372, PMID 31319102, PMID 31329313, PMID 31437325, PMID 31442495, PMID 31522849, PMID 31676085
2018 (3), R01AT004435 (3), U19AI095261 (2), 2019 (1), R01AI068074 (1), U01AI125290 (1), U01AI138907 (1), U01AI173032 (1), U19AI066738 (1), U19AI070345 (1), U19AI104209 (1), U19AI136053 (1), U44AI165328 (1), UL1TR001082 (1)